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Cell-free fetal DNA based non-invasive prenatal testing of aneuploidy: a contemporary systematic 
assessment 
 
Abstract 
Key content: 
  Non-invasive prenatal testing (NIPT) refers to testing which utilises cell-free fetal DNA 
(cffDNA) to test for aneuploidy, as opposed to non-invasive prenatal diagnosis (NIPD) which 
uses cffDNA to diagnose fetal sex, Rhesus D status and monogenic disorders. This review 
focuses on screening for aneuploidy. 
 NIPT is a screening test and needs confirmatory invasive testing in cases of a high-
risk/positive result. 
 NIPT demonstrates high sensitivities and specificities according to our recent meta-analysis  
although it is less accurate for Trisomy 18, Trisomy 13, monosomy X and sex chromosomal 
aneuploidies compared to Trisomy 21. 
 It is imperative that the implications of false positive and false negative results are 
investigated and considered in a clinical context. 
 
Learning objectives:  
 To be able to discuss NIPT with patients including its test accuracy and disadvantages 
 To be up to date with the implementation of NIPT in the National Health Service 
 
Ethical Issues: 
 NIPT requires careful counselling as patients may consider it a ‘trivial’ routine blood test, 
without fully understanding the implications of a high-risk/positive result. 
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  There are issues surrounding other diagnoses NIPT can potentially reveal including maternal 
cancers, maternal sex chromosome aneuploidies, and milder fetal phenotypes.  
 
Keywords: cell-free fetal DNA, non-invasive prenatal testing, cffDNA NIPT, aneuploidy, antenatal 
screening 
 
Introduction 
This article will focus upon the use of cell-free fetal DNA-based non-invasive prenatal testing (cffDNA 
NIPT) which is heralded as one of the biggest advances in antenatal care since the invention of 
ultrasound scanning. NIPT refers to screening for aneuploidy (an abnormal number of 
chromosomes), and therefore as a screening test requires confirmatory invasive testing in cases of 
positive/high-risk results. This is not to be confused with non-invasive prenatal diagnosis (NIPD), 
which although is also based on cell-free fetal DNA, it is considered diagnostic and therefore does 
not require further testing. NIPD is used to determine fetal sex, fetal Rhesus status, monogenic 
disorders, and is considered in a separate TOG article. The remainder of this article will focus on 
aneuploidy. The aim of this review is to provide clinicians with sufficient information to counsel 
women for NIPT. We will present test accuracy data, highlight the limitations of NIPT, discuss the 
ethical issues surrounding this relatively new test, outline current guidance, and describe its likely 
future role in the antenatal care pathway. 
 
Basis of test technique 
cffDNA comprises of small fragments of fetal DNA, thought to originate from trophoblast. These 
fragments circulate in maternal plasma and form approximately 10% of the DNA fragments in 
maternal plasma (Figure 1) (1). It is present in reliably measurable levels for aneuploidy screening 
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from 10 weeks gestation, and is cleared quickly from the maternal circulation hours after delivery, 
making it specific to that pregnancy. The commercial sector has shown particular interest in NIPT 
which has enabled the technology to develop at an unprecedented rate, but potential 
commercialisation is not without consequence.  
 
Insert Figure 1 about here 
 
The ability to identify fetal chromosomal anomalies (principally aneuploidy) has been possible since 
2011, with the introduction of massively parallel sequencing (MPS). The premise of aneuploidy 
testing is different to that of NIPD (see TOG article ‘XXX’). In aneuploidy, the amount of DNA from 
each chromosome is quantified and common autosomal trisomies are detected based on a 
difference in the proportion of each chromosome (e.g. chromosome 21 in the case of Trisomy 21, 
compared to the other chromosomes from that fetus). Following complex biostatical analysis, a 
result of ‘low-risk’ or ‘high-risk’ is given. The technology of MPS has continued to advance and two 
different subtypes are now recognised: (a) massively parallel shotgun sequencing (MPSS) whereby 
the whole genome is randomly sequenced, and (b) ‘targeted’ MPS in which only specific genomic 
regions known to contain the chromosome (or single nucleotide polymorphism (SNP)) of interest are 
sequenced and compared to reference regions.  
Test Accuracy 
We recently published a systematic review and meta-analysis in the British Journal of Obstetrics and 
Gynaecology which informs data on test accuracy of NIPT and NIPD in singleton pregnancies (2). This 
review is different from another recent review by Gil et al. published in 2015 as we only included 
cohort studies (reducing risk of bias compared to case-control studies which do not represent the 
true incidence of a condition in the population). We also performed bivariate meta-analysis which is 
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considered superior to univariate meta-analysis as it allows for the correlation between the 
sensitivity and specificity within the same study and is therefore more representative of the true 
population. The review comprised of 117 papers and looked at all conditions possible, although only 
the results relating to aneuploidy are presented in this article (see Table 1).  
 
Insert Table 1 about here 
 
NIPT for Trisomy 21 and Trisomy 18 demonstrated high sensitivity and specificity (Table 1). Results 
for Trisomy 13 revealed a comparably lower sensitivity, the exact reasons for which are yet to be 
elucidated, although is thought to be related to the low guanine-cytosine (GC) content known to 
exist in chromosome 13. Monosomy X demonstrated reduced sensitivity compared to Trisomy 21 
and 18, although it was evaluated by fewer studies which equated to many fewer tests (146344 tests 
vs. 6712 tests Trisomy 21 vs. Monosomy X respectively). We also performed a sensitivity analysis 
(results not shown) to evaluate the effect of population risk on Trisomy 21 test accuracy by removing 
the 5 studies which assessed accuracy in women with an average pre-test risk of aneuploidy. This 
demonstrated no significant difference in test accuracy in high and average risk populations. 
Unfortunately there was an insufficient number of eligible studies to meta-analyse 47XXX, 47XXY, 
47XYY and Trisomy 16. Due to the very low prevalence of sex chromosome aneuploidy (SCA), the 
95% confidence intervals were very wide (2). Gil et al. (3) pooled all the SCA results (n=56/6755 tests 
in singleton pregnancies with a SCA, excluding Monosomy X) to perform a meta-analysis and 
reported a detection rate of 93.0% (95%CI 85.8-97.8%) and false positive rate of 0.14% (0.06-0.24%). 
Maternal SCA is believed to contribute to reduced SCA test accuracy as often these conditions have a 
mild phenotype if the fetus survives. Mosaicism (maternal, placental and fetal) has also been 
reported as a contributing factor to false results.  The ethical implications of testing for SCA are 
discussed below. 
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Multiple pregnancy 
Our meta-analysis did not include multiple pregnancies as there is a dearth of data looking at NIPT in 
multiple pregnancies. The recent meta-analysis by Gil et al. (3) reported a Trisomy 21 detection rate 
of 93.7% (95% CI 83.6-99.2%) and false positive rate of 0.23% (95% CI 0.00-0.92%) in twin 
pregnancies (n=430 pregnancies, 5 studies) demonstrating lower sensitivity than testing in singleton 
pregnancies. One may hypothesise that the larger placental mass in multiple pregnancies, which 
presents a higher fraction of circulating cffDNA compared to singletons (4, 5) would lead to more 
accurate NIPT results. However, testing in multiple pregnancies presents unique challenges. In 
dizygotic twins aneuploidy discordance is a significant issue and there can be nearly a two-fold inter-
twin difference in cffDNA fraction which means that the affected fetus may have a cffDNA fraction 
below the threshold of 4% required for testing whilst the unaffected twin may contribute a high 
cffDNA fraction; therefore the total cffDNA fraction may appear sufficient and produce a false 
negative (low-risk) result (6, 7). Testing in monozygotic twins theoretically should be easier as they 
produce identical DNA molecules but chorionicity must be certain. Another problem is that of single 
twin demise as the effect that cffDNA from the demised twin has on the NIPT result is not known. As 
a result of the aforementioned factors, various professional bodies do not currently recommend 
NIPT for aneuploidy in twin pregnancies, including the Royal College of Obstetricians and 
Gynaecologists (RCOG) (8) and American College of Obstetricians and Gynecologists (ACOG) (9). 
However, it is available privately in the UK which causes dilemmas when a high-risk result is 
reported. More clinical studies are needed to investigate the unique challenges these pregnancies 
present for NIPT. 
 
Benefits of NIPT 
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There are a multitude of benefits of NIPT as reflected by its rapid progress. It is a non-invasive test 
and thus does not have the risks of chorionic villus sampling (CVS) and amniocentesis: pain, small 
risk of infection and the 0.22% (95%CI -0.71 to 1.16%) and 0.11% (95% CI -0.04 to 0.26%) procedure-
related risk of miscarriage associated with CVS and amniocentesis respectively (10). As mentioned 
previously cffDNA is cleared quickly from the maternal circulation so is specific to that pregnancy. 
The test itself has a quick processing time, with the potential for results to be reported in 3-5 
working days - equivalent to QF-PCR testing for invasive samples. However, in the clinical setting 
processing time depends on the demand for NIPT.  
Disadvantages of NIPT 
Technical – false, inconclusive and failed results 
Test accuracy is not 100% as there are false negative and false positive results, and occasions when 
the test will not produce a result – termed inconclusive test results. Our review highlighted the fact 
that false and inconclusive results were poorly reported for all indications in published data, 
although the rate of inconclusive results has been quoted as 1.9-6.4% samples (11). This information 
is vital as some studies have shown that those who have an inconclusive result are more likely to 
have a chromosomal aberration, and of those who have an inconclusive result first time round, 20% 
will have a failed repeat NIPT sample (12). One particular issue was the different quality control (QC) 
standards which meant that studies with less stringent QC standards would report a false negative 
or false positive result in a low quality sample, whereas others with more stringent criteria may 
report it as inconclusive or a ‘failed’ sample. The lack of guidance on QC standards was recently 
acknowledged by The International Society Prenatal Diagnosis (ISPD) who advised the development 
of specific guidelines (11). When evaluating test accuracy data, false and inconclusive result rates are 
vital, particularly when the test is potentially to be offered to the entire obstetric population, 
irrespective of background risk. The commonest reasons offered by study authors for their false and 
inconclusive results were:  
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 Low fetal DNA fraction in the blood sample which is measured by specific markers of fetal DNA 
such as RASSF1A.  
 A “vanishing” twin which has disappeared prior to the woman’s dating ultrasound scan may 
cause a false positive result if they are non-identical, and is likely to remain an issue even as 
technology advances. 
 Confined placental mosaicism (CPM) whereby the fetus and placenta have two different cell-
lines. As the fetal DNA fragments originate from the placenta, NIPT is unable to distinguish 
between the two. This is also something which is unlikely to be overcome, despite continued 
advances in the test technology but it should be noted that this is an issue for invasive placental 
sampling (CVS) as well. 
 NIPT can detect maternal cancers and maternal mutations which result in false positives, and 
have ethical implications (see below). 
 
Effects on medical training 
NIPT will have an effect on Fetal Medicine Specialists, as the number of invasive tests performed 
since the introduction of NIPT in the USA has decreased by rates as high as a 53% reduction in 
amniocentesis and 77% reduction in CVS, based on clinical data (as reviewed by (13)). This pattern is 
believed to be replicated in the public healthcare system of the UK as well (14) ,Therefore potentially 
doctors will become de-skilled or have insufficient training opportunities (15). This will not only 
affect doctors’ performance of invasive testing, but will also have implications on their ability to 
perform other invasive fetal procedures such as fetoscopic laser ablation, which require similar entry 
techniques. 
Financial cost at present 
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In the UK NIPT is only available on a private basis in some areas at present; with tests costing £300-
£900 therefore it is dividing populations as only patients with a higher socioeconomic status are able 
to undergo testing, although it is likely that the cost of NIPT will fall (16). 
 
Ethical Issues 
Informed consent 
NIPT raises many ethical issues which are being intensely debated. Testing for Trisomy 21, 18 and 13 
has been commercially available since 2011 but some believe that its introduction into clinical 
practice has been too fast and the ethical implications not fully explored. A major concern is that 
women and their families do not understand the potential sequelae of the test and view it as just 
another “routine” antenatal blood test (17), not one where the results may lead to a very difficult 
decision between potentially terminating the pregnancy, or continuing with a pregnancy whereby 
the baby could have a condition with a wide spectrum of severity. The importance of adequate pre-
test counselling is thus paramount, with clinicians understanding that their priorities of test accuracy 
is different to patients’ priority of test safety for their fetus (18). Clinicians also need to understand 
that a substantial proportion of couples will undergo testing for information so that they are able to 
better plan for the arrival of a baby with a chromosomal abnormality (14). Similar concerns exist for 
any screening test in pregnancy e.g. combined screening for Down syndrome and there is an online 
NHS Patient Decision Aid for ‘Diagnostic Testing for Down Syndrome’ however this does not include 
NIPT at present (19). There are a myriad of written materials, and online e-learning packages being 
developed for parents considering NIPT to enable fully informed consent. 
Sex chromosome aneuploidy (SCA) 
As mentioned previously, screening for SCA is considered less accurate than screening for autosomal 
aneuploidy. One of the main reasons study authors offer for this reduced accuracy is the presence of 
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maternal SCAs (20), which are often unknown because the phenotype may appear normal. In the 
UK, screening for SCAs is not part of conventional screening. Nevertheless, testing for SCA using NIPT 
is offered in the private sector. Consequently this can create a problem if a maternal SCA is 
diagnosed as it can be associated with learning difficulties, or reduced fertility. There is also the 
question of what to do with the result. Often if an SCA is severe the pregnancy will miscarry, 
however if the fetus survives then the offspring may be mildly affected, but then have the stigma of 
a genetic abnormality which otherwise may have remained undetected. 
 
Detection of maternal health problem 
Another matter which has recently come to light is the ability of NIPT to detect maternal cancer – a 
distressing and anxiety-inducing result, perhaps even more so in the context of antenatal testing, 
although some may also view this as a benefit of NIPT as it allows earlier treatment. Cases have also 
been reported whereby previously unknown maternal genetic abnormalities have been detected as 
a consequence of abnormal NIPT results. This adds another layer of complexity to consenting 
women for NIPT. It also creates more issues which need careful consideration, such as effect on the 
mother’s future insurance policies as highlighted by Bianchi et al. (21) 
 
Current Guidance 
There is no official guidance in the UK at present regarding the use of cffDNA for aneuploidy. The 
RCOG published a Scientific Impact Paper ‘Non-invasive prenatal testing for chromosomal 
abnormality using maternal plasma DNA’ in March 2014 which stated that “while the [NIPT] result is 
much more accurate than existing screening strategies, it is still not a diagnostic assay”, although the 
authors believed that “in time, this technology [NIPT] is likely to become the primary screen for 
chromosomal abnormalities in pregnancy for Down syndrome” in the NHS and that “all obstetricians 
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should have knowledge of the counselling issues involved” (8). In January 2016 the UK National 
Screening Committee (UKNSC) published a press release recommending the evaluative 
implementation of NIPT as a contingent screening test (i.e. a second-line screening test) for women 
with a risk higher than 1:150 on conventional screening (either nuchal translucency [NT] ultrasound 
scan, serum β-hCG and PAPP-A; or serum β-hCG , AFP, oestriol and inhibin-A), which in the case of a 
high-risk result on NIPT would then require diagnostic invasive testing (22). How this evaluation will 
be performed is currently being decided. ACOG (9) released a Committee Opinion in September 
2015 recommending conventional combined testing as first-line screening for women in the general 
obstetric population, although they state that any woman may undergo NIPT but she must be 
counselled appropriately, and a positive (high-risk) NIPT result should not be the basis of a decision 
for termination, and the result should be confirmed by invasive testing. In the case of an 
inconclusive/failed test result, ACOG advocate invasive testing and a detailed ultrasound scan. 
 
The Future of NIPT 
Many health care professionals believe that NIPT will be implemented in routine NHS antenatal care. 
How it will be implemented in the NHS is in the process of being determined.  
 
Insert Table 2 & 3 about here 
 
In order for a screening test to be considered appropriate to implement, it must satisfy various 
criteria as outlined by Wilson and Jugner (23). There have been a plethora of papers published on 
various models of NIPT screening implementation for Down Syndrome with different cut-offs, costs 
and clinical pathways (14, 16, 24-30). One important aspect to consider when evaluating these 
models is the prevalence of the disease in the test population as this will influence the positive-
11 
 
predictive value (PPV) of the test i.e. if a woman has a positive NIPT result, what is the likelihood that 
the result is a true positive in her case. In a low-risk population with a low disease prevalence, there 
will be a greater proportion of positive results which are false-positive. Therefore models based on 
women above the age of 35 years for example, may not be applicable to the NHS general obstetric 
population. Morris et al. created a robust model based on the UK screening population and 
calculated that by using NIPT in the NHS as a contingent screening test following a combined 
screening risk cut-off >1:150 this detects fewer Down syndrome cases compared to combined 
screening (11.26 vs. 13.24 respectively, equating to missing 2/10,000 hypothetical cases), however 
contingent screening does have fewer procedure-related miscarriages (0.06 vs 0.80/10,000 cases 
respectively), and costs the same as current Down syndrome testing when NIPT is priced at £500 
(see Table 2 and Table 3). Whereas if it was to be introduced as a first-line screening test compared 
to combined screening, this would produce more favourable outcomes (16.49 vs 13.24/10,000 cases 
detected respectively, 0.11 vs 0.80 procedure-related miscarriages), but at a higher financial cost 
(£50 more per NIPT) (16).  
 
The 5 year 'Reliable Accurate Prenatal non-invasive Diagnosis' (RAPID) project is the first study to 
evaluate the use of NIPT in the NHS (31). Women with a combined screening risk of ≥1:1000 for 
Down syndrome (n=1164 women) were offered NIPT. Results were available for 91% of participants 
with sensitivity 1.00 (95%CI 0.88-1.00) (32/32 cases) for Trisomy 21 and no false negatives. The use 
of NIPT as a contingent test afforded a reduction in invasive tests from 10 to 2.8 per Trisomy 21 case 
diagnosed. A major benefit of the RAPID study was that it assessed the performance of NIPT in an 
NHS setting (clinical and laboratory) with standardisation of technique and transparency of reporting 
of false and inconclusive results. The RAPID study reported 8 (0.7%) failed or inconclusive tests – 
much lower than previously reported. Despite the positive findings of RAPID there are still several 
issues which need to be considered. One unknown at present is NIPT uptake in the general 
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population and high-risk population, compared to current screening and invasive testing uptake. A 
recent paper by Chitty et al. (14) used the results of the RAPID study to evaluate this for the UKNSC 
and found that uptake of further testing (NIPT or invasive testing), after a conventional screening 
result of >1:150, increased from 54% to >90%. Interestingly, in those with a high-risk NIPT result, 
approximately one third decided to continue with the pregnancy which suggests that NIPT may not 
affect the rate of infants born with Down Syndrome, which has also been shown in studies in the 
USA (13). Although there are some people who believe women with a very high risk and/or who 
have abnormal ultrasound findings should have direct access to invasive testing (9). In the study by 
Chitty et al. 54% of women with a risk of >1:150 underwent invasive testing before the NIPT results 
were known. Another issue, as demonstrated by the example of Morris et al. and as with many 
screening programmes, a balance has to be made between detection rates, false negative rates and 
cost-effectiveness. Although the increased uptake of further testing improves the detection rate, as 
a result of the high cost of NIPT at present it is not cost-effective to introduce NIPT as the first-line 
screening test with studies favouring contingent NIPT screening (14, 16, 27, 28, 30). Although, as the 
authors highlight, the cost of NIPT will decrease over time.  
How NIPT affects ultrasound scan usage will also need to be considered. Although the NT 
measurement is involved in the combined screening test, it also provides other useful information, 
for example on the risk of cardiac defects. The dating scan provides valuable information regarding 
the number of fetuses, chorionicity in multiple pregnancy or the presence of a molar pregnancy etc 
which NIPT cannot provide. A recent study exploring the utility of first-line NIPT in 251 pregnancies 
with a variety of anomalies on ultrasound did not advocate first-line NIPT in this scenario, although 
unfortunately the authors do not comment on whether the patients underwent conventional 
screening (32). 
In addition to deciding on the role that NIPT will play in the antenatal care pathway, there are other 
challenges which need to be met in terms of the logistics of procurement, and running these tests on 
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a national level, in a quality assured way, to satisfy UK National External Quality Assessment Services 
(NEQAS). Support will also be needed from Down’s Syndrome screening: quality assurance support 
service (DQASS). 
Conclusion 
NIPT demonstrated high sensitivity and specificity for Trisomy 21, 18 and 13. Development of NIPT 
has proceeded at an unprecedented rate, largely due to the commercial sector, which may have 
contributed to the poor reporting of false and inconclusive results. Some people advise caution with 
its use, particularly given the ethical implications, and the potential this technology has to reveal 
unexpected diagnoses in the mother. NIPT will change the face of prenatal testing, and it is 
important that health care professionals counselling women on NIPT provide all the information 
required to enable women to make an informed decision regarding antenatal testing, and keep up 
with the rapid advances being made in this exciting area. 
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CPD questions 
1. Testing for aneuploidy using cell-free fetal DNA is considered Non-Invasive Prenatal 
Diagnosis (NIPD). FALSE 
2. Cell-free fetal DNA remains in the maternal circulation for 3-5 days after delivery. FALSE 
3. You can reliably perform NIPT at 6 weeks. FALSE 
4. Mass spectrometry is the preferred method of assessing for aneuploidies. FALSE 
5. Case-control studies have a higher risk of bias than cohort studies. TRUE 
6. NIPT in twins is more accurate than in singletons because there is more cffDNA. FALSE 
7. Chorionic villus sampling has a 0.22% procedure-related miscarriage rate. TRUE 
8. NIPT for autosomal aneuploidy is more accurate than for SCA. TRUE 
9. Patients’ priority for testing is fetal safety. TRUE 
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10. A “vanishing twin” does not affect NIPT results. FALSE 
11. Confined placental mosaicism is where the placenta and mother have different cell lines. 
FALSE 
12. NIPT can detect maternal cancer. TRUE 
13. cffDNA avoids the problem of mosaicism. FALSE 
14. Women with an inconclusive NIPT result are less likely to have an abnormal result. FALSE 
15. A contingent screening test is used after another screening test .TRUE 
16. NIPT replaces the need for the first trimester nuchal translucency scan. FALSE 
17. Conventional first trimester screening involves nuchal translucency [NT] ultrasound scan, 
serum β-hCG and PAPP-A. TRUE  
18. Wilson’s criteria describe the requirements of a diagnostic test. FALSE 
19. The Royal College of Obstetrics and Gynaecology views NIPT for aneuploidy as a diagnostic 
test. FALSE 
20. NIPT is more accurate than existing combined screening for Trisomy 21. TRUE 
21. The National Screening Committee advocates contingent NIPT for women with a combined 
screening risk of >1:300. FALSE 
22. A positive contingent NIPT for aneuploidy does not need confirmatory invasive testing in the 
UK. FALSE 
23.  Cell free fetal DNA comprises up to 25% of DNA fragments in maternal plasma. FALSE 
24. The positive predictive value (PPV) of the test is the number of positive tests which are 
actually true positives. FALSE 
25. In the USA, NIPT has increased the rate of invasive testing. FALSE 
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Figure 1 Fragments of cell-free fetal DNA in maternal blood used in non-invasive prenatal testing 
(NIPT). Kindly provided with permission by illumina. 
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Table 1: Summary results of test accuracy of cell-free fetal DNA non-invasive prenatal testing 
NB All analyses performed by bivariate meta-analysis, apart from where indicated by (*) which 
indicates univariate analysis was performed 
 
Condition  Number 
of studies 
(tests) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Diagnostic Odds 
Ratio (95% CI) 
Positive 
likelihood 
ratio (95% CI) 
Negative 
likelihood ratio  
(95% CI) 
Trisomy 21 31  
(148344) 
0.994  
(0.983 to 0.998) 
0.999  
(0.999 to 1.00) 
285903  
(124215 to 658053) 
1720  
(1111 to 2662) 
0.006 (0.002 to 
0.017) 
 Trisomy 18 24  
(146940) 
0.977  
(0.952 to 0.989) 
0.999  
(0.998 to 1.00) 
68110  
(29137 to 159209) 
1569  
(810 to 3149) 
0.023 (0.011 to 
0.048) 
Trisomy 13* 16 
(134691 
0.906  
(0.823 to 0.958) 
1.00  
(0.999 to 1.00) 
2788  
(285 to 27252) 
453  
(26 to 7864) 
0.188 (0.080 to 
0.44039) 
Monosomy X 8  
(6712) 
0.929  
(0.741 to 0.984) 
0.999  
(0.995 to 0.999) 
18849  
(2277 to 156069) 
1337  
(213 to 8407) 
0.071 (0.017 to 
0.292) 
Table 2 Outcomes of testing strategies in a screening population of 10,000 women (taken from 
Morris et al. 2014 (27)) assumed 69% uptake of DS screening using the combined test, 80% uptake of 
NIPT as contingent screening for unaffected pregnancies, and 90% for affected pregnancies. 69% 
uptake of NIPT as first-line screening. DS= Down Syndrome; NIPT= non-invasive prenatal testing. 
 
Testing 
strategy 
Screening 
risk cut-off 
(1 in ) 
Number 
undergoing 
screening 
Number 
undergoing 
NIPT 
Number 
with a 
positive 
NIPT 
result 
Number 
having an 
invasive 
diagnostic 
test 
Number of 
procedure-
related 
miscarriages 
Number of 
DS cases 
detected 
DS 
screening 
using the 
combined 
test 
150 6,881.66 0  160.59 0.80 13.24 
NIPT as 
contingent 
testing 
150 6,881.66 153.75 13.30 11.48 0.06 11.26 
 500 6,881.66 361.43 14.75 12.71 0.06 12.31 
 1000 6,881.66 591.02 15.26 13.13 0.07 12.55 
 2000 6,881.66 912.32 15.85 13.63 0.07 12.78 
NIPT as 
first-line 
screening 
- 0 6881.66 28.02 22.03 0.11 16.49 
 
 
Table 3 Costs of testing strategies in a screening population of 10,000 women (taken from Morris 
et al.2014 (27)) assumed 69% uptake of DS screening using the combined test, 80% uptake of NIPT 
as contingent screening for unaffected pregnancies, and 90% for affected pregnancies. 69% uptake 
of NIPT as first-line screening. DS= Down Syndrome; NIPT= non-invasive prenatal testing. 
 
Testing strategy Screening 
risk cut-
off (1 in ) 
Cost per 
NIPT test 
(£) 
(A) Cost of 
screening 
(£000s) 
(B) Cost 
of NIPT 
(£000s) 
(C) Cost of invasive 
diagnostic tests 
(£000s)* 
(A) + (B) 
+ (C) 
(£000s) 
DS screening using the 
combined test 
150  200 0 79 279 
NIPT as contingent 
screening 
150 
 
50 200 8 6 213 
 150 250 200 39 6 244 
 150 500 200 78 6 283 
 150 750 200 116 6 322 
 500 50 200 18 6 225 
 500 250 200 91 6 298 
 500 500 200 183 6 389 
 500 750 200 274 6 480 
 1000 50 200 30 6 237 
 1000 250 200 149 6 356 
 1000 500 200 298 6 505 
 1000 750 200 448 6 655 
 2000 50 200 46 7 253 
 2000 250 200 230 7 438 
 2000 500 200 461 7 668 
 2000 750 200 691 7 898 
NIPT as first-line 
screening 
 50 0 438 11 449 
  250 0 1642 11 1825 
  500 0 3535 11 3546 
  750 0 5255 11 5266 
 
 
